Published on 11 Apr 2018
Cellmid Limited (ASX:CDY) CEO Maria Halasz provides a show and tell
updating Proactive Investors on progress and strategies for the
company’s international portfolio of products, including the world’s
first non-injectable filler product.
Speaking on growth drivers,
Halasz says, "as far as our consumer health
business is concerned; we definitely have new product ranges, we've got
our e-commerce platform and new distribution channels in new geographic
regions that will drive sales and growth.
http://www.4-traders.com/CELLMID-LIMITED-10357055/
http://www.4-traders.com/CELLMID-LIMITED-10357055/
As far as our biotech
portfolio is concerned... we are meeting our intellectual leaders, but
the actual patents are owned by the company... it's cost effective but
more importantly it really is wide spread development of a really large
portfolio of patents."
No comments:
Post a Comment